Scancell Holdings PLC's (LON:SCLP) Dr Cliff Holloway presents at the Proactive One2One Virtual Conference. The company's lead drug, SCIB-1, developed from its ImmunoBody technology, has recently entered a phase II clinical trial in the UK. The study will initially assess the safety and efficacy of the treatment in 25 people with a metastatic form of skin cancer, melanoma. SCIB-1 will be used in harness with Merck’s checkpoint inhibitor Keytruda.
Scancell Holdings PLC: Proactive One2One Virtual Conference
Quick facts: Scancell Holdings PLC
Price: 14.3 GBX
Market Cap: £103.27 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE